Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2012 4
2013 17
2014 13
2015 31
2016 29
2017 24
2018 35
2019 23
2020 12
2021 5
2022 3
2023 4
2024 3
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
Non-small-cell lung cancer.
Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. Gridelli C, et al. Among authors: karachaliou n. Nat Rev Dis Primers. 2015 May 21;1:15009. doi: 10.1038/nrdp.2015.9. Nat Rev Dis Primers. 2015. PMID: 27188576 Review.
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM; INSIGHT 2 investigators. Wu YL, et al. Among authors: karachaliou n. Lancet Oncol. 2024 Aug;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5. Lancet Oncol. 2024. PMID: 39089305 Clinical Trial.
Mechanisms of resistance to osimertinib.
Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Lazzari C, et al. Among authors: karachaliou n. J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30. J Thorac Dis. 2020. PMID: 32642198 Free PMC article. Review.
Clinical assessment of immune-related adverse events.
Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Sosa A, et al. Among authors: karachaliou n. Ther Adv Med Oncol. 2018 Mar 30;10:1758835918764628. doi: 10.1177/1758835918764628. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29623110 Free PMC article. Review.
Overcoming MET-mediated resistance in oncogene-driven NSCLC.
Reischmann N, Schmelas C, Molina-Vila MÁ, Jordana-Ariza N, Kuntze D, García-Roman S, Simard MA, Musch D, Esdar C, Albers J, Karachaliou N. Reischmann N, et al. Among authors: karachaliou n. iScience. 2023 May 29;26(7):107006. doi: 10.1016/j.isci.2023.107006. eCollection 2023 Jul 21. iScience. 2023. PMID: 37534190 Free PMC article.
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series.
Le X, Eisert A, Hsia TC, Raut NV, Ahmad A, Chan OSH, De Bondt C, Farrugia D, Froesch P, González-Cao M, Hendriks L, Hochmair MJ, Mazieres J, O'Sullivan H, Popat S, Samol J, van der Wekken AJ, Yang TY, Tho LM, Himpe U, Lam WS, Lee KWC, Petrini I, Berghoff K, Karachaliou N, Joshi K, Vlassak S, Chang GC. Le X, et al. Among authors: karachaliou n. Clin Lung Cancer. 2025 Jun;26(4):338-346.e1. doi: 10.1016/j.cllc.2025.02.013. Epub 2025 Feb 21. Clin Lung Cancer. 2025. PMID: 40140342 Free article. No abstract available.
Avelumab in non-small-cell lung cancer.
Rosell R, Karachaliou N. Rosell R, et al. Among authors: karachaliou n. Lancet Oncol. 2018 Nov;19(11):1423-1424. doi: 10.1016/S1470-2045(18)30683-1. Epub 2018 Sep 24. Lancet Oncol. 2018. PMID: 30262188 No abstract available.
Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer.
Rosell R, Karachaliou N, Fancelli S, Arrieta O, Troncone G, Cao P. Rosell R, et al. Among authors: karachaliou n. Transl Lung Cancer Res. 2020 Aug;9(4):945-947. doi: 10.21037/tlcr-20-716. Transl Lung Cancer Res. 2020. PMID: 32953471 Free PMC article. No abstract available.
HER3 as a Therapeutic Target in Cancer.
Karachaliou N, Lazzari C, Verlicchi A, Sosa AE, Rosell R. Karachaliou N, et al. BioDrugs. 2017 Feb;31(1):63-73. doi: 10.1007/s40259-016-0205-2. BioDrugs. 2017. PMID: 28000159 Review.
Tumor mutational burden as predictive factor of response to immunotherapy.
Gonzalez-Cao M, Viteri S, Karachaliou N, Aguilar A, García-Mosquera JJ, Rosell R. Gonzalez-Cao M, et al. Among authors: karachaliou n. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S358-S361. doi: 10.21037/tlcr.2018.10.03. Transl Lung Cancer Res. 2018. PMID: 30705855 Free PMC article. No abstract available.
196 results